Señales en vivo de 048530.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 01:27):
Our systems believe the stock currently is overvalued by -0.17% compare to its pairs and should correct downwards.

iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs...

Stats
Volumen de hoy	101 390
Volumen promedio	129 125
Capitalización de mercado	209.11B
EPS	KRW-11.66 ( Q1 \| 2024-03-31 )
Próxima fecha de ganancias	( KRW0 ) 2024-08-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW9.23 (0.15%)

Correlación (AI algo v.1.1b): Overvalued: -0.17% KRW6 300.90 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.01 (neutral)

Signal:(59.123) Neutral

iNtRON Biotechnology, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

iNtRON Biotechnology, Correlación - Moneda/Commodity

-0.22
( neutral )

-0.30
( neutral )

0.02
( neutral )

-0.27
( neutral )

0.10
( neutral )

0.08
( neutral )

iNtRON Biotechnology, Finanzas

Annual	2023
Ingresos:	KRW9.59B
Beneficio Bruto:	KRW4.56B (47.58 %)
EPS:	KRW-292.11

FY	2023
Ingresos:	KRW9.59B
Beneficio Bruto:	KRW4.56B (47.58 %)
EPS:	KRW-292.11

FY	2022
Ingresos:	KRW14.01B
Beneficio Bruto:	KRW8.45B (60.36 %)
EPS:	KRW168.38

Financial Reports:

No articles found.

iNtRON Biotechnology, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

iNtRON Biotechnology,

iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.